✦ LIBER ✦

Tolerance and Efficacy of Extracranial Radiation Therapy During Ipilimumab Immunotherapy for Metastatic Melanoma

✍ Scribed by Barker, C.A.; Postow, M.A.; Callahan, M.K.; Khan, S.; Beal, K.; Parhar, P.K.; Lee, N.Y.; Yamada, Y.; Wolchok, J.D.

Book ID: 122909460
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 76 KB
Volume: 84
Category: Article
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2012.07.1745

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined Ipilimumab and Radiation Therap

Combined Ipilimumab and Radiation Therapy for Metastatic Melanoma

✍ Menzel, P.L.; Minor, D.R.; Abendroth, R.E. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Response of Extracranial Lesions After T

Response of Extracranial Lesions After Treatment of Metastatic Melanoma With Cranial Radiation and Ipilimumab

✍ Schoenfeld, J.D.; Mahadevan, A.; Floyd, S.R.; Dyer, M.A.; Catalano, P.; Alexande 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Predictive value of serum S100B for moni

Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy

✍ Hauschild; Engel; Brenner; Gläser; Mönig; Henze; Christophers 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB

Feasibility and Efficacy of Stereotactic

Feasibility and Efficacy of Stereotactic Body Radiation Therapy Using Robotic Radiosurgery as Curative Treatment for Metastatic Thyroid Carcinoma

✍ Wang, H.; Meng, M.; Jiang, C.; Qian, D.; Zhao, L.; Yuan, Z.; Wang, P. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 78 KB

The benefits of adjuvant radiation thera

The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma

✍ Shefali Agrawal; John M. Kane III; Beverly A. Guadagnolo; William G. Kraybill; M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

A phase II trial of high-dose cisplatin

A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma

✍ Thomas A. Steffens; Dean F. Bajorin; Paul B. Chapman; David R. Lovett; Beverly V 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 831 KB

Cisplatin and dacarbazine are used widely in the treatment of metastatic melanoma. To evaluate high-dose cisplatin and dacarbazine, 32 patients with metastatic melanoma were treated with cisplatin 50 mg/m\* and dacarbazine 350 mg/m2 daily for three days repeated at 28-day intervals. Their median age